Platform-derived thymic cell therapy
Immune dysfunction in aging and disease (Immunodeficiencies, Transplant-related, Autoimmune)
Key Facts
About Thymmune Therapeutics
Thymmune Therapeutics is a private, preclinical-stage biotech founded in 2019 and based in Cambridge, Massachusetts. The company is pioneering an iPSC-derived thymic cell therapy platform, enhanced by machine learning, to address immune dysfunction stemming from thymic involution in aging and disease. With significant non-dilutive funding from ARPA-H and seed financing from notable venture capital firms, Thymmune is building its team and platform to advance therapies for immunodeficiencies, transplant-related complications, and autoimmune disorders. The company represents a novel convergence of regenerative medicine, immunology, and computational biology.
View full company profile